Switching from efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF) or rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks

被引：0

作者：

Orkin, C. ^{[1
]}

DeJesus, E. ^{[2
]}

Ramgopal, M. ^{[3
]}

Crofoot, G. ^{[4
]}

Ruane, P. ^{[5
]}

LaMarca, A. ^{[6
]}

Mills, A. ^{[7
]}

Van der Cam, B. ^{[8
]}

De Wet, J. ^{[9
]}

Rockstroh, J. ^{[10
]}

Lazzarin, A. ^{[11
]}

Rijnders, B. ^{[12
]}

Podzamczer, D. ^{[13
]}

Thalme, A. ^{[14
]}

Stoeckle, M. ^{[15
]}

Chu, H. ^{[16
]}

Porter, D. ^{[16
]}

Liu, H. ^{[16
]}

Cheng, A. ^{[16
]}

Quirk, E. ^{[16
]}

SenGupta, D. ^{[16
]}

Cao, H. ^{[16
]}

机构：

[1] Barts Hlth NHS Trust, London, England

[2] Orlando Immunol Ctr, Orlando, FL USA

[3] Midway Immunol & Res Ctr, Ft Pierce, FL USA

[4] Crofoot Res Ctr, Houston, TX USA

[5] Peter Jerome Ruane, Los Angeles, CA USA

[6] Therafirst Med Ctr, Ft Lauderdale, FL USA

[7] Mills Clin Res, Los Angeles, CA USA

[8] Clin Univ St Luc, Brussels, Belgium

[9] JJ de Wet, Vancouver, BC, Canada

[10] Bonn Univ Hosp, Bonn, Germany

[11] Osped San Raffaele, Milan, Italy

[12] Erasmus MC, Rotterdam, Netherlands

[13] Hosp Univ Bellvitge, Barcelona, Spain

[14] Karolinska Univ Hosp, Stockholm, Sweden

[15] Univ Hosp Basel, Basel, Switzerland

[16] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

来源：

HIV MEDICINE | 2017年 / 18卷

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

P20

引用

页码：21 / 21

页数：1

共 50 条

[41] 48-WEEK SAFETY AND EFFICACY OF SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) IN CHRONIC HBV ASIAN PATIENTS WITH TDF RISK FACTORS (RF) [J].

Ahn, Sang Hoon ;

Kao, Jia-Horng ;

Hann, Hie-Won ;

Scott, Fung ;

Trinh, Huy ;

Nguyen, Tuan Trong ;

Paik, Seung Woon ;

Gaggar, Anuj ;

Flaherty, John ;

Yee, Leland ;

Jump, Belinda ;

Sethi, Shalini ;

Wu, George ;

Chan, Carol Yee Kwan .

GUT, 2020, 69 :A73-A74

[42] 1 YEAR SAFETY AND EFFICACY DATA IN CHRONIC HBV PATIENTS WITH RISK FACTORS FOR TENOFOVIR DISOPROXIL FUMARATE (TDF) AFTER SWITCHING FROM TDF TO TENOFOVIR ALAFENAMIDE (TAF) [J].

Pan, Calvin Q. ;

Gane, Edward ;

Seto, Wai-Kay ;

Janssen, Harry L. ;

Caruntu, Florin ;

Kim, Hyung Joon ;

Abdurakhmanov, Dzhamal ;

Nishiguchi, Shuhei ;

Bae, Ho ;

Mo, Shuyuan ;

Suri, Vithika ;

Gaggar, Anuj ;

Flaherty, John F. ;

Kao, Jia-Horng ;

Brunetto, Maurizia Rossana ;

Buti, Maria .

GASTROENTEROLOGY, 2018, 154 (06) :S1132-S1133

[43] Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/tenofovir DF or efavirenz emtricitabine/tenofovir DF through 96 weeks [J].

Porter, Danielle P. ;

Kulkarni, Rima ;

Garner, Will ;

Miller, Michael D. ;

White, Kirsten L. .

ANTIVIRAL THERAPY, 2017, 22 (06) :495-502

[44] Uptake of 2-1-1 Dosing of Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) as an Alternative to Daily PrEP at a Sexual Health Clinic in San Francisco [J].

Bacon, Oliver ;

Sankaran, Madeline ;

Levy, Montica ;

Kohn, Robert P. ;

Cohen, Stephanie E. .

SEXUALLY TRANSMITTED DISEASES, 2022, 49 (10S) :S38-S38

[45] A combination regimen by lopinave/litonawe (LPV/r), emtricitabine and tenofovir alafenamide fumarate (FTC/TAF) for treatment of novel coronavirus pneumonia (TARCoV) [J].

Jiang Hua ;

Wang Yu ;

Wang Kai ;

Yang Xingxiang ;

Zhang Jiancheng ;

Deng Hongfei ;

Wang Lu ;

Zeng Jun .

Chinese Journal of Emergency Medicine, 2020, (03) :E006-E006

[46] Comparing effectiveness and tolerability of emtricitabine/tenofovir alafenamide (F/TAF) with emtricitabine/tenofovir disoproxil fumarate (F/TDF) in HIV-1 infected adult patients in routine clinical practice: a cross cohort analysis [J].

Esser, S. ;

Stellbrink, H-J ;

Heiken, H. ;

Meynard, J-L ;

Thorpe, D. ;

Schreiber, S. ;

Heinzkill, M. ;

Sahali, S. ;

Ramroth, H. ;

Haubrich, R. .

HIV MEDICINE, 2019, 20 :67-68

[47] Evaluation of the Efficacy and Safety of Switching to Tenofovir, Emtricitabine, and Rilpivirine in Treatment-Experienced Patients [J].

Surgers, Laure ;

Valin, Nadia ;

Viala, Celine ;

Boyd, Anders ;

Fonquernie, Laurent ;

Girard, Pierre-Marie ;

Morand-Joubert, Laurence ;

Meynard, Jean-Luc .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2015, 68 (01) :E10-E12

[48] The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile [J].

Squillace, Nicola ;

Ricci, Elena ;

Menzaghi, Barbara ;

De Socio, Giuseppe Vittorio ;

Passerini, Simone ;

Martinelli, Canio ;

Mameli, Maria Sabrina ;

Maggi, Paolo ;

Falasca, Katia ;

Cordier, Laura ;

Celesia, Benedetto Maurizio ;

Salomoni, Elena ;

Di Biagio, Antonio ;

Pellicano, Giovanni Francesco ;

Bonfanti, Paolo .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 :5515-5520

[49] TENOFOVIR DISOPROXIL FUMARATE (TDF) VERSUS EMTRICITABINE PLUS TDF (FTC/TDF) FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN PATIENTS WITH PERSISTENT VIRAL REPLICATION RECEIVING ADEFOVIR DIPIVOXIL: FINAL WEEK 168 RESULTS [J].

Berg, Thomas ;

Marcellin, Patrick ;

Moeller, Bernd ;

Trinh, Huy N. ;

Chan, Sing ;

Suarez, Emilio ;

Snow-Lampart, Andrea ;

Peschell, Kenneth J. ;

Borroto-Esoda, Katyna ;

Hirsch, Kenneth R. ;

Frederick, David .

HEPATOLOGY, 2010, 52 (04) :387A-388A

[50] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) AT 96 WEEKS IN CHRONIC HBV (CHB) PATIENTS WITH RISK FACTORS FOR USE OF TENOFOVIR DISOPROXIL FUMARATE (TDF) [J].

Chan, Henry Lik-Yuen ;

Buti, Maria ;

Flisiak, Robert ;

Ryder, Stephen ;

Streinu-Cercel, Adrian ;

Flaherty, John F. ;

Gaggar, Anuj ;

Mo, Shuyuan ;

Subramanian, G. Mani ;

Zoulim, Fabrian ;

Andreone, Pietro ;

Marcellin, Patrick .

GUT, 2018, 67 :A97-A97

← 1 2 3 4 5 →